Related Experiment Videos
Randomized clinical trials in melanoma
Kathryn Spanknebel1, Larissa Temple, Spiros Hiotis
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. spanknek@mskcc.org
Surgical Oncology Clinics of North America
|April 4, 2002
Abstract:
Efforts to improve the survival of patients with metastatic melanoma have led to 67 prospective randomized clinical trials investigating the use of agents comprising three main areas of therapy: systemic chemotherapy-based regimens, immunotherapy, and vaccine therapy
Insights
This review examines 67 clinical trials for metastatic melanoma, focusing on systemic chemotherapy, immunotherapy, and vaccine therapy to improve patient survival rates.
Area of Science:
- Oncology
- Clinical Trials
- Melanoma Research
Background:
- Metastatic melanoma presents significant survival challenges.
- Advancements in cancer treatment are crucial for improving patient outcomes.
Purpose of the Study:
- To systematically review prospective randomized clinical trials in metastatic melanoma.
- To analyze therapeutic strategies including chemotherapy, immunotherapy, and vaccine therapy.
Main Methods:
- Conducted a comprehensive literature search for relevant clinical trials.
- Included 67 prospective randomized clinical trials in the analysis.
- Categorized interventions into chemotherapy, immunotherapy, and vaccine therapy.
Main Results:
- Identified 67 prospective randomized clinical trials.
- Therapeutic agents investigated fall into three primary categories.
- Focus on systemic chemotherapy-based regimens, immunotherapy, and vaccine therapy.
Conclusions:
- Multiple therapeutic avenues are being explored to enhance survival in metastatic melanoma.
- Clinical trials are essential for evaluating novel treatment strategies.
- Further research is needed to optimize treatment protocols for metastatic melanoma.